GlassScriptPhysician profile
Edward Fruitman
NPI 1558434134
$430,970.08
in general payments reported to CMS, 2019-2025
37 companies · $101K in 2025
The $101K reported for 2025 was more than what 98% of Psychiatry providers received nationally (typical 2025 total: $176).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $30K · 2020: $7,684 · 2021: $39K · 2022: $114K · 2023: $97K · 2024: $42K · 2025: $101K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $205K · Food and Beverage: $16K · Consulting Fee: $13K · Travel and Lodging: $6,024 · Education: $281.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $204,667.31 |
| Food and Beverage | $15,702.35 |
| Consulting Fee | $13,210.00 |
| Travel and Lodging | $6,023.52 |
| Education | $281.34 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Neurocrine Biosciences, INC. | $112,686.01 | 2019-2025 | Ingrezza |
| Teva Pharmaceuticals USA, INC. | $82,968.90 | 2019-2025 | Uzedy, Austedo Xr, Austedo Xr |
| Allergan, INC. | $80,118.32 | 2019-2023 | |
| Abbvie INC. | $78,571.39 | 2021-2025 | |
| Alkermes, INC. | $35,188.59 | 2019-2025 | Lybalvi, Aristada |
| E.R. Squibb & Sons, L.L.C. | $29,603.20 | 2024-2025 | Cobenfy |
| Idorsia Pharmaceuticals US INC | $4,785.34 | 2023 | Quviviq |
| Lumenis Be INC | $1,365.71 | 2023 | M22 |
| Axsome Therapeutics, INC. | $622.18 | 2022-2025 | Auvelity |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $610.94 | 2020-2025 | Caplyta |
| Merz North America, INC. | $601.80 | 2019-2024 | |
| Bausch Health US, LLC | $575.27 | 2019-2025 | Aplenzin, Wellbutrin |
| Janssen Pharmaceuticals, INC | $317.16 | 2019-2023 | Invega Sustenna |
| Indivior INC. | $302.86 | 2019-2025 | Sublocade, Perseris |
| Avanir Pharmaceuticals, INC. | $253.24 | 2019-2022 |
Show all 37 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Corium, LLC | $246.96 | 2022-2025 | Azstarys |
| Neos Therapeutics, LP | $216.91 | 2023-2024 | Adzenys Xr-Odt |
| Supernus Pharmaceuticals, INC. | $215.09 | 2022-2024 | Qelbree, Qelbree |
| Boston Scientific Corporation | $206.08 | 2023-2024 | Wavewriter Alpha Prime 16 |
| Merck Sharp & Dohme LLC | $196.24 | 2020-2023 | Belsomra |
| Tris Pharma INC | $156.77 | 2022-2025 | Dyanavel Xr |
| Alfasigma USA, INC. | $136.54 | 2021-2022 | |
| Takeda Pharmaceuticals U.S.A., INC. | $135.03 | 2024-2025 | Trintellix |
| Noven Therapeutics, LLC | $118.23 | 2020-2024 | Xelstrym, Secuado |
| Vanda Pharmaceuticals INC. | $104.70 | 2020-2024 | Fanapt, Hetlioz |
| Galderma Laboratories, L.P. | $96.67 | 2021-2023 | |
| Novo Nordisk INC | $79.93 | 2022-2025 | Wegovy |
| Orexo US, INC. | $77.94 | 2019-2021 | |
| Currax Pharmaceuticals LLC | $69.95 | 2019-2021 | |
| Shire North American Group INC | $64.85 | 2019 | |
| Lundbeck LLC | $55.31 | 2021-2022 | |
| Almatica Pharma LLC | $46.45 | 2023 | Loreev Xr, Sertraline Hcl |
| Collegium Pharmaceutical, INC. | $45.51 | 2025 | Jornay Pm |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $43.63 | 2021 | |
| Eisai INC. | $34.65 | 2020-2021 | |
| Adlon Therapeutics L.P. | $28.17 | 2021 | |
| Jazz Pharmaceuticals INC. | $23.56 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Edward Fruitman listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.